Your browser doesn't support javascript.
loading
Stevens-Johnson Syndrome Induced by Vandetanib
Annals of Dermatology ; : S343-S345, 2011.
Article en En | WPRIM | ID: wpr-165614
Biblioteca responsable: WPRO
ABSTRACT
Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QT interval prolongation, and hypertension. Though a number of randomized, doubleblind studies, including cutaneous adverse events attributed to vandetanib, have been reported along with these general symptoms, no case of Stevens-Johnson syndrome (SJS) has been reported. This paper demonstrates a case of SJS induced by vandetanib.
Asunto(s)
Palabras clave
Texto completo: 1 Índice: WPRIM Asunto principal: Piperidinas / Quinazolinas / Proteínas Tirosina Quinasas / Síndrome de Stevens-Johnson / Carcinoma de Pulmón de Células no Pequeñas / Receptores de Factores de Crecimiento Endotelial Vascular / Proliferación Celular / Diarrea / Receptores ErbB / Hipertensión Tipo de estudio: Clinical_trials Idioma: En Revista: Annals of Dermatology Año: 2011 Tipo del documento: Article
Texto completo: 1 Índice: WPRIM Asunto principal: Piperidinas / Quinazolinas / Proteínas Tirosina Quinasas / Síndrome de Stevens-Johnson / Carcinoma de Pulmón de Células no Pequeñas / Receptores de Factores de Crecimiento Endotelial Vascular / Proliferación Celular / Diarrea / Receptores ErbB / Hipertensión Tipo de estudio: Clinical_trials Idioma: En Revista: Annals of Dermatology Año: 2011 Tipo del documento: Article